The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity

IUBMB Life

Volumn 48, Issue 2, 1999, Pages 139-141

  Yantiri, Ferda ^a   Andersen, Julie K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Ferritin; Iron; MPTP; Oxidative stress; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FERRITIN; IRON;

BRAIN DEGENERATION; HUMAN; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; DOPAMINE AGENTS; FERRITINS; HUMANS; IRON; MPTP POISONING; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0032704374     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/152165499307134     Document Type: Review

References (43)

1. Koeppen, A. H. (1995) The history of iron in the brain. J. Neurol. Sci. 134, 1-9.
2. Beard, J. L., Connor, J. D., and Jones, B. C. (1993) Brain iron: Location and function. Prog. Food Nutr. Sci. 17, 183-221.
3. Gutteridge, J. M. C., Halliwell, B., and Treffry, A. (1983) Effect of ferritin containing fractions with different iron loading on lipid peroxidation. J. Biochem. 209, 557-560.
4. Glinka, Y., Gassen, M., and Youdim, M.B.H. (1996) Iron and neurotransmitter function in brain. In Metals and Oxidative Damage in Neurological Disorders (Connors, J. R., ed.). pp. 1-12, Plenum Publishing Corp., New York.
5. Harrison, P. M., and Arosio, P. (1996) The ferritins: Molecular properties, iron storage function, and cellular regulation. Biochim. Biophys. Acta 1275, 161-203.
6. Arosio, P., Levi, S., Samtambrogio, P., Cozzi, A., Luzzago, A., Cesareni, G., and Albertini, A. (1991) Structural and functional studies of human ferritin H and L chains. Curr. Stud. Hematol. Blood Trans. 58, 127-131.
7. Olanow, C. W. (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann. Neurol. 32, S2-S9.
8. Gerlach, M., Ben-Shachar, D., Riederer, P., and Youdim, M. B. H. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807.
9. Youdim, B. H. M., and Riederer, P. (1997) Understanding Parkinson's disease. Sci. Am. 276, 52-59.
10. Beal, F. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130.
11. Gassen, M., and Youdim, M. B. H. (1997) The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharm. Toxicol. 80, 159-166.
12. Jenner, P., and Olanow, W. (1998) Understanding cell death in Parkinson's Disease. Ann. Neurol. 44, S72-S84.
13. Sziraki, I., Mohanakumar, K. P., Rauhala, P., Kim, H. G., Yeh, K. J., and Chiueh, C. C. (1998) Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 85, 1101-1111.
14. Lan, J., and Jiang, D. H. (1997) Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104, 649-660.
15. Spencer, J. P. E., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., and Halliwell, B. (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanism of formation involving reactive oxygen species. J. Neurochem. 71, 2112-2122.
16. Bartzokis, G., Cummings, J., Perlman, S., Darwood, B., and Mintz, J. (1999) Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56, 569-574.
17. Connor, J. R., Menzies, S. L., St. Martin, S. M., and Mufson, E. J. (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 31, 75-83.
18. Valberg, L. S., Flanagan, P. R., Kertesz, A., and Ebers, G. C. (1989) Abnormalities in iron metabolism in multiple sclerosis. Can. J. Neurol. Sci. 16, 184-186.
19. Lehermitte, J., Kraus, W., and McAlpine, M. A. (1924) On the occurrence of abnormal deposits of iron in the brain in Parkinson's disease with special references to its location. J. Neurol. Phychopathol. 5, 195-208.
20. Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P., and Marsden, C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
21. Riederer, P., Dirr, A., Goetz, M., Sofic, E., Jellinger, K., and Youdim, M. B. H. (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 32, S101-S104
22. Youdim, B. H. M., BenShachar, D., and Riederer, P. (1993) The possible role of iron in etiopathology of Parkinson's disease. Movement Disorders 8, 1-14.
23. Gorell, J. M., Ordidge, R. J., Brown, G. G., Deniau, J.-C., Buderer, N. M., and Helpern, J. A. (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology. 45, 1138-1143.
24. Ye, F. Q., Allen, P. S., and Martin, W. R. (1996) Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Movement Disorders 11, 243-249.
25. Smith, M. A., Harris, P. L. R., Sayre, L. M., and Perry, G. (1997) Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94, 9866-9868.
26. Riederer, P., Sofic, E., Rausch, W.-D., Schmidt, B., Reynolds, G. P., Jellinger, K., and Youdim, M. B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brain. J. Neurochem. 52, 515-520.
27. Good, P. F., Olanow, C. W., and Perl, D. P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study. Brain Res. 593, 343-346.
28. Hirsch, E. C., Brandel, J.-P., Galle, P.. Javoy-Agid, F., and Agid, Y. (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: An x-ray microanalysis. J. Neurochem. 56, 446-451.
29. Uitti, R. J., Rajput, A. H., Rozdilsky, B., Bickis, M., Wolling, T., and Yuen, W. K. (1989) Regional metal concentrations in Parkinson's disease, and other chronic neurological diseases, and control brain. Can. J. Neurol. Sci. 16, 310-314.
30. Galazka-Friedmand, J., Bauminger, E. R., Friedman, A., Barcikowska, M., Hechel, D., and Nowik, I. (1996) Iron in parkinsonian and control substantia nigra. Movement Disorders 11, 8-16.
31. Gilissen, E. P., Ghosh, P., Jacobs, R. E., and Allman, J. M. (1998) Topographical localization of iron in brains of the aged fat-tailed dwarf lemur (Cheirogaleus medius) and gray lesser mouse lemur (Microcebus murinus). Am. J. Primatol. 45, 291-299.
32. Dexter, D. T., Carayon, A., Vidailher, M., Ruberg, M., Agid, F., and Agid, Y. (1990) Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55, 16-20.
33. Mann, V. M., Cooper, J. M., Daniel, S. E., Srai, K., Jenner, P., Marsden, C. D., and Schapira, A. H. (1994) Complex I, iron, and ferritin in Parkinson's disease. Ann. Neurol. 36, 876-881.
34. Connor, J. R., Snyder, B. S., and Arosio, P. (1995) Quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer diseased brains. J. Neurochem. 65, 717-724.
35. Faucheux, B. A., Martin, M. E., Beaumont, C., Hauw, J. J., Agid, Y., and Hirsch, E. C. ( 1998) Proteins involved in the regulation of intracellular iron (H- and L-ferritin, iron regulatory protein) in the mesencephalon of patients with Parkinson's disease. Abst. Soc. Neurosci. 574.16.
36. Yoshida, T., Tanaka, M., Sotomatsu, A., and Hirai, S. (1995) Activated microglia cause superoxide-mediated release of iron from ferritin. Neurosci. Lett. 190, 21-24.
37. Double, K. L., Maywald, M., Schmittel, M., Riederer, P., and Gerlach, M. (1998) In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70, 2492-2499.
38. Jenner, P. (1992) Oxidative damage in neurodegenerative disease. Lancet 344, 796-798.
39. Yong, V. W., Perry, T. L., and Krisman, A. A. ( 1986) Depletion of glutathione in brainstems of mice by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63, 56-60.
40. Przedborski, S., Kostic, V., Jackson-Lewis, V., Naini, A. B., Simonetti, S., Fahn, S., Carlson, E., Epstein, C. J., and Cadet, J. L. (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurosci. 12, 1658-1667.
41. Mochizuki, H., Imai, H., Yokomizo, K., Murata, Y., Hattori, N., and Mizuno, Y. (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168, 251-253.
42. Di Monte, D. A., Schipper, H. M., Hetts, S., and Langston, W. (1995) Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Glia 15, 203-206.
43. Poirier, J., Donaldson, J., and Barbeau, A. (1985) The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. Biochem. Biophys. Res. Commun. 128, 25-33.